CY1120913T1 - Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους - Google Patents

Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους

Info

Publication number
CY1120913T1
CY1120913T1 CY181101081T CY181101081T CY1120913T1 CY 1120913 T1 CY1120913 T1 CY 1120913T1 CY 181101081 T CY181101081 T CY 181101081T CY 181101081 T CY181101081 T CY 181101081T CY 1120913 T1 CY1120913 T1 CY 1120913T1
Authority
CY
Cyprus
Prior art keywords
progastrin
monoclonal antibodies
methods
directed
present disclosure
Prior art date
Application number
CY181101081T
Other languages
English (en)
Inventor
Julie Pannequin
Laure Boudier
Dominique Joubert
Frédéric Hollande
Original Assignee
Progastrine Et Cancers S A R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120913(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Progastrine Et Cancers S A R L filed Critical Progastrine Et Cancers S A R L
Publication of CY1120913T1 publication Critical patent/CY1120913T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η παρούσα αποκάλυψη κατευθύνεται προς μονοκλωνικά αντισώματα προγαστρίνης, θραύσματα αυτών, συνθέσεις που περιέχουν μονοκλωνικά αντισώματα προγαστρίνης, και μεθόδους παρασκευής και χρήσης μονοκλωνικών αντισωμάτων προγαστρίνης και συνθέσεων αυτών. Η παρούσα αποκάλυψη κατευθύνεται προς μεθόδους θεραπείας του καρκίνου του παχέος εντέρου με μονοκλωνικά αντισώματα προγαστρίνης και με συνθέσεις που περιέχουν μονοκλωνικά αντισώματα προγαστρίνης ή θραύσματα αυτών. Η παρούσα αποκάλυψη επίσης κατευθύνεται προς μεθόδους που περιλαμβάνουν ανίχνευση προγαστρίνης, συμπεριλαμβανομένων μεθόδων διάγνωσης του καρκίνου του παχέος εντέρου και μεθόδων παρακολούθησης της αποτελεσματικότητας αντικαρκινικής θεραπείας σε άτομα που πάσχουν από καρκίνο του παχέος εντέρου.
CY181101081T 2009-10-16 2018-10-22 Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους CY1120913T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
PCT/EP2010/006329 WO2011045080A2 (en) 2009-10-16 2010-10-15 Monoclonal antibodies to progastrin and their uses

Publications (1)

Publication Number Publication Date
CY1120913T1 true CY1120913T1 (el) 2019-12-11

Family

ID=43086711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101081T CY1120913T1 (el) 2009-10-16 2018-10-22 Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους

Country Status (41)

Country Link
US (7) US9611320B2 (el)
EP (2) EP2488551B1 (el)
JP (3) JP5985987B2 (el)
KR (2) KR20120091221A (el)
CN (2) CN104628857A (el)
AP (1) AP2012006262A0 (el)
AR (1) AR078659A1 (el)
AU (1) AU2010306119A1 (el)
BR (1) BR112012008818B1 (el)
CA (1) CA2777691C (el)
CL (1) CL2012000914A1 (el)
CR (1) CR20120184A (el)
CU (1) CU24196B1 (el)
CY (1) CY1120913T1 (el)
DK (1) DK2488551T3 (el)
EA (2) EA029271B1 (el)
EC (1) ECSP12011796A (el)
ES (1) ES2690943T3 (el)
GE (1) GEP201706604B (el)
GT (1) GT201200114A (el)
HK (1) HK1178183A1 (el)
HN (1) HN2012000708A (el)
HR (1) HRP20181645T1 (el)
IL (2) IL219019B (el)
IN (1) IN2012DN03348A (el)
LT (1) LT2488551T (el)
MA (1) MA33747B1 (el)
MX (1) MX351635B (el)
NI (1) NI201200054A (el)
NZ (2) NZ701709A (el)
PE (1) PE20121649A1 (el)
PL (2) PL2488551T3 (el)
PT (1) PT2488551T (el)
RS (1) RS57966B1 (el)
SG (1) SG10201704933PA (el)
SI (1) SI2488551T1 (el)
TN (1) TN2012000159A1 (el)
TW (1) TWI537002B (el)
UA (1) UA106771C2 (el)
WO (1) WO2011045080A2 (el)
ZA (1) ZA201202642B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
SG10201704933PA (en) * 2009-10-16 2017-07-28 Inst Nat De La Sante Et De La Rech Medicale (Inserm) Monoclonal antibodies to progastrin and their uses
US9487582B2 (en) * 2010-01-08 2016-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods for treating pancreatic cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
KR101570404B1 (ko) * 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
US9410955B2 (en) 2011-06-01 2016-08-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method for predicting the risk of developing a colonic neoplasia
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
MX2016013686A (es) * 2014-04-18 2017-03-31 Univ New York State Res Found Anticuerpos de antigeno anti-tf humanizado.
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
AU2016324021A1 (en) * 2015-09-15 2018-04-12 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN114705858A (zh) * 2015-12-31 2022-07-05 Syncerus有限责任公司 用于评估癌症发生的风险的组合物和方法
US20190011449A1 (en) * 2015-12-31 2019-01-10 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating gastric cancer
EA037015B1 (ru) * 2015-12-31 2021-01-27 Прогастрин Э Кансер С.А Р.Л. Применение и способ для профилактики или лечения рака яичников с использованием композиции, содержащей прогастринсвязывающее антитело
KR102351556B1 (ko) * 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
KR102616819B1 (ko) * 2017-03-30 2023-12-21 프로가스트린 에 캔서스 에스.에이 알.엘. 폐암을 치료하기 위한 조성물 및 방법
WO2019110662A1 (en) * 2017-12-05 2019-06-13 Progastrine Et Cancers S.À R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
CN112004560A (zh) 2017-12-08 2020-11-27 Ecs生物识别***有限公司 癌症诊断中的放射性标记的前胃液素
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN117567611B (zh) * 2023-11-22 2024-05-14 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP2008513536A (ja) * 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
SG10201704933PA (en) * 2009-10-16 2017-07-28 Inst Nat De La Sante Et De La Rech Medicale (Inserm) Monoclonal antibodies to progastrin and their uses

Also Published As

Publication number Publication date
IL219019A0 (en) 2012-06-28
TN2012000159A1 (en) 2013-12-12
US20170306011A1 (en) 2017-10-26
US20110117086A1 (en) 2011-05-19
IL219019B (en) 2019-05-30
ES2690943T3 (es) 2018-11-23
MX351635B (es) 2017-10-23
GEP201706604B (en) 2017-01-25
NZ701709A (en) 2016-06-24
UA106771C2 (uk) 2014-10-10
IN2012DN03348A (el) 2015-10-23
IL254004A0 (en) 2017-10-31
EP2488551A2 (en) 2012-08-22
US10385125B2 (en) 2019-08-20
HRP20181645T1 (hr) 2018-12-14
DK2488551T3 (en) 2018-10-08
CU24196B1 (es) 2016-09-30
HK1178183A1 (zh) 2013-09-06
EP2488551B1 (en) 2018-07-25
JP2017212992A (ja) 2017-12-07
US20170174761A1 (en) 2017-06-22
US10385124B2 (en) 2019-08-20
EA201791876A1 (ru) 2018-01-31
MX2012004400A (es) 2012-06-27
JP6272793B2 (ja) 2018-01-31
AU2010306119A1 (en) 2012-05-03
SG10201704933PA (en) 2017-07-28
TW201119675A (en) 2011-06-16
CR20120184A (es) 2012-08-20
CN102791735A (zh) 2012-11-21
NI201200054A (es) 2012-08-20
US11299542B2 (en) 2022-04-12
RS57966B1 (sr) 2019-01-31
AP2012006262A0 (en) 2012-06-30
MA33747B1 (fr) 2012-11-01
CU20120060A7 (es) 2013-04-19
EP3421493B1 (en) 2024-01-17
BR112012008818A2 (pt) 2018-05-22
JP2015145380A (ja) 2015-08-13
NZ599971A (en) 2014-12-24
SI2488551T1 (sl) 2019-01-31
CA2777691A1 (en) 2011-04-21
WO2011045080A2 (en) 2011-04-21
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
US20200002413A1 (en) 2020-01-02
PT2488551T (pt) 2018-10-31
JP2013507138A (ja) 2013-03-04
IL254004B2 (en) 2023-06-01
US9611320B2 (en) 2017-04-04
US10377821B2 (en) 2019-08-13
ECSP12011796A (es) 2012-06-29
LT2488551T (lt) 2018-10-25
JP5985987B2 (ja) 2016-09-06
EA201200597A1 (ru) 2012-12-28
HN2012000708A (es) 2015-06-22
PL3421493T3 (pl) 2024-04-29
EA029271B1 (ru) 2018-03-30
US20170306012A1 (en) 2017-10-26
CL2012000914A1 (es) 2012-09-14
TWI537002B (zh) 2016-06-11
BR112012008818B1 (pt) 2021-10-19
CN104628857A (zh) 2015-05-20
US20180022802A1 (en) 2018-01-25
KR20120091221A (ko) 2012-08-17
GT201200114A (es) 2014-08-11
US20220195035A1 (en) 2022-06-23
WO2011045080A3 (en) 2011-07-07
PL2488551T3 (pl) 2019-01-31
CA2777691C (en) 2018-02-27
ZA201202642B (en) 2013-06-26
EP3421493A1 (en) 2019-01-02
PE20121649A1 (es) 2012-12-08
EP3421493C0 (en) 2024-01-17
KR101640520B1 (ko) 2016-07-19
US10385126B2 (en) 2019-08-20
KR20150082672A (ko) 2015-07-15

Similar Documents

Publication Publication Date Title
CY1120913T1 (el) Μονοκλωνικα αντισωματα εναντι προγαστρινης και η χρηση τους
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1119251T1 (el) Θεραπεια συνδυασμου ενος αφουκοζυλιωμενου αντισωματος cd20 με μπενδαμουστινη
CY1122144T1 (el) Αιθερες αρυλιου και χρησεις εξ αυτων
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
CY1119324T1 (el) Αντισωματα εναντιον csf-1r
CY1118933T1 (el) Anti-cxcr1 συνθεσεις και μεθοδοι
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
EA201591801A1 (ru) Лекарственные конъюгаты антител
CY1112739T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1116719T1 (el) Μεθοδοι ανιχνευσης αντισωματων αντι-φαρμακου
EA201791843A3 (ru) Способы повышения эффективности folr1 терапии рака
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
CY1122156T1 (el) Αντισωματα κατα του σχετιζομενου με τον νεφρο αντιγονου 1 και αντιγονοδεσμευτικα θραυσματα αυτων
CY1121821T1 (el) Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
CY1117234T1 (el) Μεθοδος προσδιορισμου της ευαισθησιας ασθενους στη θεραπεια αναστολης της τελομερασης
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.
CY1116592T1 (el) ΣΥΝΔΥΑΣΤΙΚΗ ΘΕΡΑΠΕΙΑ ΠΟΥ ΕΜΠΕΡΙΕΧΕΙ ΑΝΤΑΓΩΝΙΣΤΕΣ α5β1
TR200606118U (tr) İki parça entübasyon tüpü sabitleme aparatı